Safety and Efficacy of Genolimzumab (GB226) in Combination With Fruquintinib
Status:
Recruiting
Trial end date:
2022-12-01
Target enrollment:
Participant gender:
Summary
This study is a multi-center, open-label, dose-finding phase Ib clinical study with extension
phase, which is aimed at evaluating the efficacy and safety of GB226 combined with
fruquintinib in treatment of relapsed or metastatic NSCLC patients with EGFR-sensitive
mutations who have failed to respond to EGFR-TKI treatment,evaluating the pharmacokinetic
characteristics of GB226 and fruquintinib, and the immunogenicity of GB226, and preliminarily
evaluating the antitumor activity of GB226 and fruquintinib.